Navigation Links
Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Date:1/15/2014

ences.  Key hormones, including adiponectin and leptin, also showed changes characteristic of non-PWS obese patients, demonstrating that the drug was highly active in these patients and had a similar effect to that seen in non-PWS patients.

"These results are very exciting for the treatment of PWS, as most patients showed improvements in body weight, hunger-related behaviors, and body fat content, despite the increased food intake included in the trial design," explained Dr. Jennifer Miller, Associate Professor of Pediatric Endocrinology, University of Florida, and Principal Investigator for the study.  "PWS is a complex genetic disease that is difficult to treat and the results of this trial demonstrate that beloranib has a beneficial impact on this underserved patient population.  Notably, we were encouraged by reports of fullness, a first-time occurrence for PWS patients who otherwise lack the capacity to feel sated after meals."

"PWS patients remain severely impacted by their disease and are not treatable with other anti-obesity agents," added Janalee Heinemann, Director of Research & Medical Affairs for the Prader-Willi Syndrome Association (USA).  "PWS represents one of the most severe forms of genetic obesity and we welcome these results, which are a significant step towards finding a treatment for those suffering from this life threatening condition."

Beloranib, a novel obesity therapy that utilizes a unique mechanism of action, is being studied for its ability to reduce body weight and improve cardiometabolic risk factors in obese patients with and without PWS.  This study was a randomized, double-blind, placebo-controlled trial to evaluate the safety and tolerability of a dose range of beloranib administered as twice-weekly subcutaneous injections for four weeks.  The randomized treatment part of the study was follow
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
4. Zafgen Secures $45 Million in Series E Financing
5. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Research and Markets  has announced the ... by Application, and by Geography - Global Forecast to ... The medical electronics market is expected to grow at ... the world due to growing income levels, and increasing ... hypertension, and cardiovascular diseases. A growing population coupled with ...
(Date:10/2/2014)... 2, 2014  Eli Lilly and Company (NYSE: ... tabalumab­ -- being studied for the treatment of ... -- due to insufficient efficacy in two pivotal ... on safety concerns. ­­­­ In the ... primary endpoint, at either dose studied, of statistically ...
(Date:10/2/2014)...  InfinityQS International, Inc., the global authority on ... client speakers for Infusion Chicago, its 9 th ... will be held Oct. 9-10, 2014, at the ... from Coloplast, The Kellogg Company, Biomet, General Cable, ... two-day event will also include best practice presentations ...
Breaking Medicine Technology:Medical Electronics (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU) Market - Global Forecast to 2020 2Medical Electronics (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU) Market - Global Forecast to 2020 3Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 2Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 3InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 2InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 3
... SAN DIEGO, Oct. 4 To mark the beginning ... its breast cancer treatment services at its West Houston ... Emission Mammography) scanners are high-resolution breast PET systems that ... of a lesion.  The metabolic view allows physicians to ...
... ALTOONA, Pa., Oct. 4 In response ... and the importance of "aging-in-place" as an ... Technologies, LLC ("Delta") today announced the introduction ... developed to optimize the homecare therapist. ...
Cached Medicine Technology:SightLine Health Adds Naviscan PEM Technology to Breast Cancer Treatment Services 2Delta Health Technologies ClinicalVirtuoso™ Targets Homecare Therapists 2
(Date:10/2/2014)... Robins & Morton received nine Excellence ... Contractors (ABC) of Alabama. , ABC will recognize ... Sheraton Birmingham Hotel., ,     HealthSouth Rehabilitation ... $25 Million, Obelisk Award (First Place) , ... Million to $25 Million, Obelisk Award (First Place) ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. ... control -- especially long-acting implanted devices -- could slash pregnancy ... new findings suggest. In a study of 1,400 teenage ... the girls, rates of unplanned pregnancy and abortion. Over three ... -- versus a rate of 158 per 1,000 among all ...
(Date:10/2/2014)... 1, 2014 (HealthDay News) -- Children with autism are ... fully capable of being more active, a small study ... of 29 children, some with autism and some without. ... of moderate physical activity and 70 more minutes each ... children with autism scored lower on strength, but had ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... that pull out all the stops to rescue surgical ... but the cost of such heroism is questionable, a ... 5 percent better at saving elderly patients with life-threatening ... with less intensity, said senior author Dr. Amir Ghaferi. ...
(Date:10/1/2014)... strongly associated with Alzheimer,s disease; however, researchers are still ... causal agent of the onset and development of the ... beta-amyloid is not harmful when found in isolation but ... to form the so-called amyloid fibrils , "We are ... with multiple ones because each aggregate of peptide, which ...
Breaking Medicine News(10 mins):Health News:Robins & Morton wins nine awards from Associated Builders and Contractors 2Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 2Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 3Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 4Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2
... IntraHealth International will highlight its ... the developing world during the 36th annual ... D.C., May 26-30. Hosted by the Global Health ... = Healthy Communities," focuses on the ways in which ...
... groups, headed by Prof. Nils Brose of the Max Planck ... on behalf of the European Union, to study the role ... the research teams is headed by Prof. Kobi Rosenblum of ... has been awarded a grant of 600,000 Euro. The topic ...
... reports MS medication possession ratio of 86 percent for ... Multiple sclerosis patients managed by a specialty pharmacy program ... risk of being hospitalized for their disease than those ... according to a study completed by HealthCore, Inc.HealthCore researcher ...
... Velocity,s intelligent search capabilities such as geo-spatial search, content ... May 19 Vivisimo ( www.vivisimo.com ), a leading ... that Bupa, an international health and care company with ... selected the Vivisimo Velocity Search Platform ...
... to provide sun protection, laughs and college scholarship ... Today non-profit Cancer for College launches a new ... proceeds from the sunscreen sales will go to ... granting college scholarships to cancer survivors and amputees.To ...
... mice might explain progression from skin to breathing condition ... secreted by eczema-damaged skin might trigger asthma in children, ... study of mice with an eczema-like condition, which suggested ... trigger substance might help prevent asthma. , An estimated ...
Cached Medicine News:Health News:IntraHealth International Addresses Capacity Building and Open Source Technologies at Tech-Themed Global Health Conference 2Health News:MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR 2Health News:MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR 3Health News:Vivisimo Powers Site Search on Bupa's Leading Health Information Websites Worldwide 2Health News:Photos: Will Ferrell Sunscreen to Launch Just in Time for Summer 2Health News:Molecule in Skin May Link Eczema and Asthma 2
... cup system has been designed to enhance ... and cluster hole configurations. The objective of ... on three primary modes: Tilt, migration and ... result in initial and long-term fixation. The ...
Optimal solution for normal acetabulum and younger patients....
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
Medicine Products: